Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash from Financing Activities (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Cash from Financing Activities for 7 consecutive years, with -$378.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 601.21% year-over-year to -$378.6 million, compared with a TTM value of -$378.5 million through Dec 2025, down 196.59%, and an annual FY2025 reading of -$378.5 million, down 196.59% over the prior year.
  • Cash from Financing Activities was -$378.6 million for Q4 2025 at Keros Therapeutics, down from $140000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $156.8 million in Q1 2024 and bottomed at -$378.6 million in Q4 2025.
  • Average Cash from Financing Activities over 5 years is $17.1 million, with a median of $2.6 million recorded in 2023.
  • The sharpest move saw Cash from Financing Activities surged 138708.57% in 2022, then crashed 601.21% in 2025.
  • Year by year, Cash from Financing Activities stood at $28.4 million in 2021, then surged by 116.13% to $61.4 million in 2022, then rose by 12.76% to $69.3 million in 2023, then rose by 9.08% to $75.5 million in 2024, then plummeted by 601.21% to -$378.6 million in 2025.
  • Business Quant data shows Cash from Financing Activities for KROS at -$378.6 million in Q4 2025, $140000.0 in Q3 2025, and $17000.0 in Q2 2025.